Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma-Reference-Cited by-同舟云学术

Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma

Published:2015-09-01 Issue:10 Volume:90 Page:888-891
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Binder Moritz¹,Rajkumar S. Vincent²,Gertz Morie A.²,Lacy Martha Q.²,Dispenzieri Angela²,Buadi Francis K.²,Dingli David²,Hayman Suzanne R.²,Lust John A.²,Kapoor Prashant²,Lin Yi²,Go Ronald S.²,Hwa Yi L.²,Kyle Robert A.²,Kumar Shaji K.²

Affiliation:

1. Department of Internal Medicine; Mayo Clinic; Rochester Minnesota

2. Division of Hematology; Mayo Clinic; Rochester Minnesota

Funder

American Society of Hematology Early Investigator Award

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24107/fullpdf

Reference20 articles.

1. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma;Rajkumar;Blood,2005

2. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group;Rajkumar;J Clin Oncol,2006

3. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma;Rajkumar;J Clin Oncol,2008

4. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

5. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial;Rajkumar;Lancet Oncol,2010

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Response Assessment in Multiple Myeloma: Histogram Analysis of Total Tumor Apparent Diffusion Coefficient based on Whole‐body Diffusion‐weighted MR Imaging;Journal of Magnetic Resonance Imaging;2023-12-13

2. Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial;eJHaem;2023-08-03

3. Prediction of Early Treatment Response in Multiple Myeloma Using MY-RADS Total Burden Score, ADC, and Fat Fraction From Whole-Body MRI: Impact of Anemia on Predictive Performance;American Journal of Roentgenology;2022-02

4. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains;European Journal of Haematology;2021-11-19

5. Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma;Frontiers in Immunology;2021-08-19